- Home
- GXAI vs OVID Comparison
GXAI vs OVID Comparison
Compare GXAI & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GXAI
- OVID
- Stock Information
- Founded
- GXAI 2021
- OVID 2014
- Country
- GXAI United States
- OVID United States
- Employees
- GXAI N/A
- OVID N/A
- Industry
- GXAI
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- GXAI
- OVID Health Care
- Exchange
- GXAI Nasdaq
- OVID Nasdaq
- Market Cap
- GXAI 19.7M
- OVID 20.6M
- IPO Year
- GXAI 2023
- OVID 2017
- Fundamental
- Price
- GXAI $2.08
- OVID $1.03
- Analyst Decision
- GXAI
- OVID Strong Buy
- Analyst Count
- GXAI 0
- OVID 4
- Target Price
- GXAI N/A
- OVID $3.13
- AVG Volume (30 Days)
- GXAI 14.7M
- OVID 1.5M
- Earning Date
- GXAI 08-13-2025
- OVID 08-13-2025
- Dividend Yield
- GXAI N/A
- OVID N/A
- EPS Growth
- GXAI N/A
- OVID N/A
- EPS
- GXAI N/A
- OVID N/A
- Revenue
- GXAI $198,711.00
- OVID $6,651,000.00
- Revenue This Year
- GXAI N/A
- OVID N/A
- Revenue Next Year
- GXAI N/A
- OVID $5.32
- P/E Ratio
- GXAI N/A
- OVID N/A
- Revenue Growth
- GXAI 72158.55
- OVID 1070.95
- 52 Week Low
- GXAI $1.00
- OVID $0.24
- 52 Week High
- GXAI $7.50
- OVID $1.47
- Technical
- Relative Strength Index (RSI)
- GXAI 62.20
- OVID 80.83
- Support Level
- GXAI $1.03
- OVID $0.84
- Resistance Level
- GXAI $2.96
- OVID $1.02
- Average True Range (ATR)
- GXAI 0.24
- OVID 0.09
- MACD
- GXAI 0.15
- OVID 0.03
- Stochastic Oscillator
- GXAI 54.64
- OVID 91.71
About GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.